AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24839251 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute total sleep deprivation (TSD)
Number of subjects: 14
Study 24839251 — intervention group
Group type: COMPARATOR
Intervention: Normal sleep (8.5 hours)
Number of subjects: 14
Study 22549117 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (2400 mg)
Number of subjects: 22
Study 22549117 — intervention group
Group type: COMPARATOR
Intervention: No compound (control)
Number of subjects: 22
Study 19027366 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen/progestin hormone therapy
Number of subjects: 0
Study 19027366 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective oestrogen receptor modulators
Number of subjects: 0
Study 19027366 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0
Study 19027366 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 0
Study 19027366 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate
Number of subjects: 0
Study 17709852 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week staged bilateral arthroplasties
Number of subjects: 90
Study 17709852 — intervention group
Group type: COMPARATOR
Intervention: Matched randomised controls (unilateral arthroplasties)
Number of subjects: 90
Study 16302862 — intervention group
Group type: EXPERIMENTAL
Intervention: FAST-KD
Number of subjects: 48
Study 16302862 — intervention group
Group type: COMPARATOR
Intervention: GRAD-KD
Number of subjects: 48
Study 11863154 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.4 ml lidocaine with 1:80,000 epinephrine
Number of subjects: 30
Study 11863154 — intervention group
Group type: COMPARATOR
Intervention: 4.4 ml 3% prilocaine with 0.031 U/ml felypressin
Number of subjects: 30
Study 10445367 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF gel (1%)
Number of subjects: 280
Study 10445367 — intervention group
Group type: EXPERIMENTAL
Intervention: SnF2 gel (1%)
Number of subjects: 280
Study 10445367 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 280
Study 8539345 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.8 g/kg)
Number of subjects: 45
Study 8539345 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (20 mg)
Number of subjects: 45
Study 8539345 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for both experiments)
Number of subjects: 45
Study 2189696 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 55
Study 2189696 — intervention group
Group type: COMPARATOR
Intervention: Control group with Continuous Positive Pressure Ventilation (CPPV)
Number of subjects: 55
Study 229983 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation plus CCNU (36 cases)
Number of subjects: 102
Study 229983 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation plus BCNU (34 cases)
Number of subjects: 102
Study 229983 — intervention group
Group type: COMPARATOR
Intervention: Irradiation alone (32 cases)
Number of subjects: 102
Study 31652344 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem hemitartrate formulation (5 mg orodispersible tablet)
Number of subjects: 30
Study 31652344 — intervention group
Group type: COMPARATOR
Intervention: Zolpidem hemitartrate formulation (5 mg sublingual tablet)
Number of subjects: 30
Study 31080095 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body MRI (WB-MRI)
Number of subjects: 370
Study 31080095 — intervention group
Group type: COMPARATOR
Intervention: Standard pathways
Number of subjects: 370
Study 28049139 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-2206
Number of subjects: 43
Study 28049139 — intervention group
Group type: COMPARATOR
Intervention: Everolimus
Number of subjects: 43
Study 26304466 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg/d
Number of subjects: 1121
Study 26304466 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg/d
Number of subjects: 1121
Study 26304466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1121
Study 23915042 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo analgesic treatments (choice between treatments)
Number of subjects: 0
Study 23915042 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo treatment (choice of treatment)
Number of subjects: 0
Study 23915042 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory discomfort paradigm (choice between treatments)
Number of subjects: 0
Study 20689466 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestogen therapy
Number of subjects: 1941
Study 20689466 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy alone
Number of subjects: 1941
Study 20689466 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1941
Study 19298337 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day regimen with 500 mg clarithromycin b.i.d., 500 mg metronidazole t.i.d., and 500 mg amoxicillin t.i.d.
Number of subjects: 0
Study 19298337 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day regimen containing 500 mg clarithromycin b.i.d., 1 g amoxicillin b.i.d., and 20 mg omeprazole b.i.d.
Number of subjects: 0
Study 19298337 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day clarithromycin, metronidazole, and amoxicillin regimen
Number of subjects: 0
Study 19298337 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day clarithromycin, amoxicillin, and omeprazole regimen
Number of subjects: 0
Study 19298337 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with atrophic gastritis receiving clarithromycin, metronidazole, and amoxicillin
Number of subjects: 0
Study 19298337 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with atrophic gastritis receiving clarithromycin, amoxicillin, and omeprazole
Number of subjects: 0
Study 18021144 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin group (n = 44)
Number of subjects: 176
Study 18021144 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother's arms group (n = 44)
Number of subjects: 176
Study 18021144 — intervention group
Group type: COMPARATOR
Intervention: Nursery group (n = 88)
Number of subjects: 176
Study 18021144 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant foot temperature in skin-to-skin group
Number of subjects: 176
Study 18021144 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal axillar temperature
Number of subjects: 176
Study 15469650 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity exercise (40 min at 40% VO2max) performed 3.5 hours after the test meal
Number of subjects: 12
Study 15469650 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity exercise (40 min at 40% VO2max) performed the afternoon before the test meal
Number of subjects: 12
Study 15469650 — intervention group
Group type: COMPARATOR
Intervention: No exercise (control group)
Number of subjects: 12
Study 12613400 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogic breathing exercises (pranayama)
Number of subjects: 30
Study 12613400 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 9519749 — intervention group
Group type: EXPERIMENTAL
Intervention: Picotamide, 300 mg, 3 tablets/day
Number of subjects: 30
Study 9519749 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 3 tablets/day
Number of subjects: 30
Study 7857349 — intervention group
Group type: EXPERIMENTAL
Intervention: pidotimod
Number of subjects: 60
Study 7857349 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 2699544 — intervention group
Group type: EXPERIMENTAL
Intervention: Kanamicine sulphate daily for 6 days followed by polidesossiribonucleotide for 24 days
Number of subjects: 303
Study 2699544 — intervention group
Group type: COMPARATOR
Intervention: Untreated (control group)
Number of subjects: 303
Study 1000518 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A: DTIC, vincristine, BCNU
Number of subjects: 274
Study 1000518 — intervention group
Group type: COMPARATOR
Intervention: Regimen B: DTIC, vincristine, hydroxyurea
Number of subjects: 274
Study 1000518 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen C: DTIC, actinomycin D, BCNU
Number of subjects: 274
Study 1000518 — intervention group
Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 274
Study 1000518 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimens A and C
Number of subjects: 274
Study 29072092 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-week outpatient rehabilitation programme followed by a six-week home exercise programme
Number of subjects: 19
Study 29072092 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed-start rehabilitation programme)
Number of subjects: 19
Study 28224927 — intervention group
Group type: EXPERIMENTAL
Intervention: Age- and sex-specific gene expression score (ASGES) >15
Number of subjects: 2370
Study 28224927 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive testing
Number of subjects: 2370
Study 26635079 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 g/d prebiotic supplementation
Number of subjects: 30
Study 26635079 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric placebo
Number of subjects: 30
Study 23605175 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention (eight weekly individual phone sessions)
Number of subjects: 45
Study 23605175 — intervention group
Group type: COMPARATOR
Intervention: Control (scripted follow-up phone call)
Number of subjects: 45
Study 21382514 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-free chewing gum (test group)
Number of subjects: 2720
Study 21382514 — intervention group
Group type: COMPARATOR
Intervention: Control group (unspecified)
Number of subjects: 2720
Study 19145092 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent prostate brachytherapy (PB)
Number of subjects: 231
Study 16642608 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture at Yongquan (KI 1) plus antiemetic
Number of subjects: 88
Study 16642608 — intervention group
Group type: COMPARATOR
Intervention: Antiemetic only (Control)
Number of subjects: 88
Study 14669032 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy (not specified)
Number of subjects: 106
Study 10992837 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean hand acupressure performed 30 min before induction of anaesthesia, applied to the K-K9 acupuncture point, disc remained for at least 24 h.
Number of subjects: 0
Study 10992837 — intervention group
Group type: COMPARATOR
Intervention: Placebo group, no specific intervention details provided.
Number of subjects: 0
Study 8559421 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin 3 g/day
Number of subjects: 203
Study 8559421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study 1893304 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (10 mg bid, titrated to 18.6 +/- 0.7 mg/day)
Number of subjects: 8
Study 1893304 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 8
Study 1893304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6407410 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly exchange of CVC via a guidewire
Number of subjects: 62
Study 6407410 — intervention group
Group type: COMPARATOR
Intervention: Historical controls (not specified in detail)
Number of subjects: 62
Study 6407410 — intervention group
Group type: EXPERIMENTAL
Intervention: CVC exchange
Number of subjects: 62
Study 30412234 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial + text health-warning message
Number of subjects: 1859
Study 30412234 — intervention group
Group type: COMPARATOR
Intervention: No health-warning message
Number of subjects: 1859
Study 30412234 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit-flavored varieties
Number of subjects: 1859
Study 30412234 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower nicotine content (0.0% vs. 0.05% vs. 0.5%)
Number of subjects: 1859
Study 30412234 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower prices
Number of subjects: 1859
Study 30474735 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrupted Sutures (IS)
Number of subjects: 161
Study 30474735 — intervention group
Group type: COMPARATOR
Intervention: Continuous Sutures (CS)
Number of subjects: 161
Study 28929068 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic myringoplasty
Number of subjects: 120
Study 28929068 — intervention group
Group type: COMPARATOR
Intervention: Microscopic myringoplasty
Number of subjects: 120
Study 25645091 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxalobacter formigenes (700 million, twice a day)
Number of subjects: 80
Study 25645091 — intervention group
Group type: COMPARATOR
Intervention: Potassium magnesium citrate (30 mEq, twice a day)
Number of subjects: 80
Study 23539907 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 8 mg/16 mg as add-on therapy to ACE-inhibitors
Number of subjects: 35
Study 20931329 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil 600 mg
Number of subjects: 10
Study 20931329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 19011428 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (40 mg single dose)
Number of subjects: 23
Study 19011428 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (7.5 mg single dose)
Number of subjects: 23
Study 19011428 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (steady-state treatment)
Number of subjects: 23
Study 16980161 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 30
Study 16980161 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 30
Study 16980161 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 30
Study 16980161 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprenolol
Number of subjects: 30
Study 12745490 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch alone
Number of subjects: 1384
Study 12745490 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray alone
Number of subjects: 1384
Study 12745490 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (nicotine patch + nicotine nasal spray)
Number of subjects: 1384
Study 12745490 — intervention group
Group type: COMPARATOR
Intervention: Nicotine patch alone, Nicotine nasal spray alone, Combination therapy
Number of subjects: 1384
Study 10774967 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper gastrointestinal endoscopy
Number of subjects: 53
Study 8627439 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative-free topical ointment therapy
Number of subjects: 60
Study 8627439 — intervention group
Group type: COMPARATOR
Intervention: Control (no topical treatment or as-needed therapy with a water-in-oil emollient)
Number of subjects: 60
Study 7969210 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide
Number of subjects: 57
Study 7969210 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 57
Study 2887101 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (0.1 mg/kg intravenously)
Number of subjects: 23
Study 2887101 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (0.15 mg/kg intravenously)
Number of subjects: 23
Study 29316164 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide once weekly plus dapagliflozin
Number of subjects: 0
Study 29316164 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide once weekly
Number of subjects: 0
Study 29316164 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 0
Study 27391640 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily 5% minoxidil topical foam (MTF)
Number of subjects: 322
Study 27391640 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily 2% minoxidil topical solution (MTS)
Number of subjects: 322
Study 25622626 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 112
Study 25622626 — intervention group
Group type: COMPARATOR
Intervention: CNI
Number of subjects: 112
Study 24641892 — intervention group
Group type: EXPERIMENTAL
Intervention: DepoDur (extended-release epidural morphine)
Number of subjects: 60
Study 24641892 — intervention group
Group type: COMPARATOR
Intervention: Duramorph (control)
Number of subjects: 60
Study 23310938 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg propofol (PG)
Number of subjects: 40
Study 23310938 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg thiopentone (TG)
Number of subjects: 40
Study 20083683 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass grafting
Number of subjects: 341
Study 20083683 — intervention group
Group type: COMPARATOR
Intervention: On-pump coronary artery bypass grafting
Number of subjects: 341
Study 18049395 — intervention group
Group type: EXPERIMENTAL
Intervention: Needlescopic cholecystectomy (NC)
Number of subjects: 40
Study 18049395 — intervention group
Group type: COMPARATOR
Intervention: Needlescope-assisted cholecystectomy (NAC)
Number of subjects: 40
Study 16042640 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release morphine
Number of subjects: 64
Study 16042640 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 64
Study 11826587 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty
Number of subjects: 0
Study 10207709 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple-responsible episodes
Number of subjects: 25
Study 10207709 — intervention group
Group type: COMPARATOR
Intervention: Therapist-responsible episodes
Number of subjects: 25
Study 10207709 — intervention group
Group type: COMPARATOR
Intervention: Contrast condition (previous therapist process)
Number of subjects: 25
Study 8801446 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg per day
Number of subjects: 4159
Study 8801446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4159
Study 1592970 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice with 1000 micrograms F/g
Number of subjects: 7
Study 1592970 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice with 1500 micrograms F/g
Number of subjects: 7
Study 1592970 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice with 2500 micrograms F/g
Number of subjects: 7
Study 1592970 — intervention group
Group type: COMPARATOR
Intervention: Dentifrice with 0 micrograms F/g (control)
Number of subjects: 7
Study 1592970 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-containing dentifrices (1000, 1500, 2500 micrograms F/g)
Number of subjects: 7
Study 6329092 — intervention group
Group type: EXPERIMENTAL
Intervention: pivmecillinam 400 mg every 6 h for 5 days
Number of subjects: 44
Study 6329092 — intervention group
Group type: COMPARATOR
Intervention: ampicillin 500 mg every 6 h for 5 days
Number of subjects: 44
Study 6329092 — intervention group
Group type: EXPERIMENTAL
Intervention: pivmecillinam 400 mg every 6 h for 5 days (excluding resistant strains)
Number of subjects: 44
Study 6329092 — intervention group
Group type: COMPARATOR
Intervention: ampicillin 500 mg every 6 h for 5 days (excluding resistant strains)
Number of subjects: 44
Study 6329092 — intervention group
Group type: EXPERIMENTAL
Intervention: pivmecillinam 400 mg every 6 h for 5 days (susceptible strains)
Number of subjects: 44
Study 6329092 — intervention group
Group type: COMPARATOR
Intervention: ampicillin 500 mg every 6 h for 5 days (susceptible strains)
Number of subjects: 44
Study 30799839 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic treatment coupled with lactation consultation
Number of subjects: 0
Study 30799839 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29399843 — intervention group
Group type: EXPERIMENTAL
Intervention: High Desisting Aggression group
Number of subjects: 620
Study 29399843 — intervention group
Group type: EXPERIMENTAL
Intervention: High Study Skills group
Number of subjects: 620
Study 29399843 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall dropout rate
Number of subjects: 620
Study 29399843 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable trajectories of study skills
Number of subjects: 620
Study 26964911 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet lab training
Number of subjects: 40
Study 26964911 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality lab training
Number of subjects: 40
Study 26964911 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional training)
Number of subjects: 40
Study 26964911 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry lab training
Number of subjects: 40
Study 26964911 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality simulation training
Number of subjects: 40
Study 25864252 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominopelvic binder
Number of subjects: 75
Study 22244049 — intervention group
Group type: EXPERIMENTAL
Intervention: Iferanserin 10 mg BID
Number of subjects: 121
Study 22244049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 20446586 — intervention group
Group type: EXPERIMENTAL
Intervention: Voglibose 0.2 mg three times a day
Number of subjects: 1780
Study 20446586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1780
Study 17668978 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish
Number of subjects: 33
Study 17668978 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% CHX
Number of subjects: 33
Study 17668978 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% CHX
Number of subjects: 33
Study 17668978 — intervention group
Group type: COMPARATOR
Intervention: Professional tooth cleaning
Number of subjects: 33
Study 15672372 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone switched on
Number of subjects: 55
Study 15672372 — intervention group
Group type: COMPARATOR
Intervention: Mobile phone switched off
Number of subjects: 55
Study 11958305 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous insulin infusion with dextrose 5%‐based cardioplegic solution
Number of subjects: 50
Study 11958305 — intervention group
Group type: COMPARATOR
Intervention: Sliding scale insulin treatment with normal saline 0.9%‐based cardioplegic solution
Number of subjects: 50
Study 10448871 — intervention group
Group type: COMPARATOR
Intervention: Tumor rCBF and rCBV
Number of subjects: 5
Study 10448871 — intervention group
Group type: COMPARATOR
Intervention: rCMRO2 and rOEF
Number of subjects: 5
Study 10448871 — intervention group
Group type: COMPARATOR
Intervention: Kinetic tumor rCMRGl
Number of subjects: 5